All updated as on -
The Global Hemophilia market is expected to reach USD 16.9 billion by 2030, at a CAGR of 8.11% during the forecast period 2022 to 2030.
Low or absent levels of the clotting factor VIII protein characterise haemophilia A. The treatment standard has been FVIII replacement therapy for quite some time. Haemophilia A treatment has seen dramatic shifts as FVIII has been replaced in a variety of ways, first with donated whole blood, then with plasma, and most recently with recombinant human FVIII (rFVIII) replacement therapies. Haemophilia is usually diagnosed at birth, although it can also occur later in life if the body begins to create antibodies that attack and destroy clotting components. However, this form of haemophilia is extremely rare.
As the number of therapeutic therapy options decreases and the pressure on regulatory bodies increases, research and development activities are growing. The "ecosystem" in this context means the community of people who make up the building trade. The rise in haemophilia incidence, advances in haemophilia treatment technology, and government initiatives in favour of haemophilia management all contribute to the industry's expansion.
Report Coverage
Global Hemophilia research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Hemophilia report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Hemophilia competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Hemophilia market players and analyses their core competencies in each global market sub-segments.
Due to the wide range of therapy and drug options, the haemophilia treatment market is expanding. Inhibitor therapy, over-the-counter medications, free factor replacement therapy, antifibrinolytic drugs, gene therapy, and physical therapy are just some of the common treatments and therapies for haemophilia. These factors have contributed greatly to the expansion of the haemophilia therapy market. Due to increasing government initiatives and forceful political campaigns, the haemophilia therapy business has expanded in recent years. Medical recommendations for inoculation against COVID have led to advancements in haemophilia treatment and care in recent years.
The haemophilia market is broken down into the prophylaxis market and the treatment-as-needed market. Over the coming years, the on-demand segment is expected to grow at a faster rate than the others. However, the propphylaxis market is expected to expand at a higher rate than any other throughout the anticipated time frame. An increasingly common method of treating severe haemophilia is prophylaxis, which entails giving patients repeated injections of clotting factor concentrates. The duration of this treatment depends on the severity of the patients' conditions. Taking preventative measures is expected to have positive effects on both health and productivity.
Haemophilia treatment options are broken down by kind of therapy into niche markets for things like immunological tolerance induction (ITI), replacement, and gene replacement. The replacement therapy segment is expected to maintain its dominant position during the forecasted time frame. The treatment of choice is known as replacement therapy, which helps patients recover by giving them new clotting factors to replace the ones they've lost. Gene therapy is a relatively recent medical specialisation that involves the search for defective DNA base pairs and their replacement with healthy ones. UniQure's AMT-060, a potential drug developed for the treatment of type B, is currently undergoing clinical studies. Patients with type B can benefit from the therapy by having a functioning copy of the factor IX gene implanted into liver cells.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Hemophilia market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Hemophilia market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Hemophilia market based on the below-mentioned segments:
Global Hemophilia Market, By Treatment
Global Hemophilia market, By Therapy
Global Hemophilia Market, By End User
Global Hemophilia market, Regional Analysis
Low or absent levels of the clotting factor VIII protein characterise haemophilia A. The treatment standard has been FVIII replacement therapy for quite some time. Haemophilia A treatment has seen dramatic shifts as FVIII has been replaced in a variety of ways, first with donated whole blood, then with plasma, and most recently with recombinant human FVIII (rFVIII) replacement therapies. Haemophilia is usually diagnosed at birth, although it can also occur later in life if the body begins to create antibodies that attack and destroy clotting components. However, this form of haemophilia is extremely rare.
As the number of therapeutic therapy options decreases and the pressure on regulatory bodies increases, research and development activities are growing. The "ecosystem" in this context means the community of people who make up the building trade. The rise in haemophilia incidence, advances in haemophilia treatment technology, and government initiatives in favour of haemophilia management all contribute to the industry's expansion.
Report Coverage
Global Hemophilia research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Hemophilia report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Hemophilia competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Hemophilia market players and analyses their core competencies in each global market sub-segments.
Due to the wide range of therapy and drug options, the haemophilia treatment market is expanding. Inhibitor therapy, over-the-counter medications, free factor replacement therapy, antifibrinolytic drugs, gene therapy, and physical therapy are just some of the common treatments and therapies for haemophilia. These factors have contributed greatly to the expansion of the haemophilia therapy market. Due to increasing government initiatives and forceful political campaigns, the haemophilia therapy business has expanded in recent years. Medical recommendations for inoculation against COVID have led to advancements in haemophilia treatment and care in recent years.
The haemophilia market is broken down into the prophylaxis market and the treatment-as-needed market. Over the coming years, the on-demand segment is expected to grow at a faster rate than the others. However, the propphylaxis market is expected to expand at a higher rate than any other throughout the anticipated time frame. An increasingly common method of treating severe haemophilia is prophylaxis, which entails giving patients repeated injections of clotting factor concentrates. The duration of this treatment depends on the severity of the patients' conditions. Taking preventative measures is expected to have positive effects on both health and productivity.
Haemophilia treatment options are broken down by kind of therapy into niche markets for things like immunological tolerance induction (ITI), replacement, and gene replacement. The replacement therapy segment is expected to maintain its dominant position during the forecasted time frame. The treatment of choice is known as replacement therapy, which helps patients recover by giving them new clotting factors to replace the ones they've lost. Gene therapy is a relatively recent medical specialisation that involves the search for defective DNA base pairs and their replacement with healthy ones. UniQure's AMT-060, a potential drug developed for the treatment of type B, is currently undergoing clinical studies. Patients with type B can benefit from the therapy by having a functioning copy of the factor IX gene implanted into liver cells.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2020 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2019 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Bayer AG, CSL Ltd. (CSL Behring), F. Hoffmann-La Roche AG, Grifols, S.A, Medexus Pharmaceuticals Inc., Novo Nordisk A/S, octapharma ag, Pfizer Inc., Swedish Orphan Biovitrum AB, Takeda Pharmaceuticals Company ltd |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Hemophilia Market from 2021 to 2030.
- Market Forecast for Hemophilia Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Hemophilia competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Hemophilia
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Hemophilia market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Hemophilia market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
- S.A
- Medexus Pharmaceuticals Inc.
- Novo Nordisk A/S
- octapharma ag
- Bayer AG, CSL Ltd. (CSL Behring)
- F. Hoffmann-La Roche AG
- Grifols
- Pfizer Inc.
- Swedish Orphan Biovitrum AB
- Takeda Pharmaceuticals Company ltd
Primary Target Market
- Market Players of Hemophilia
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Hemophilia market based on the below-mentioned segments:
Global Hemophilia Market, By Treatment
- On-demand
- Prophylaxis
Global Hemophilia market, By Therapy
- Replacement Therapy
- ITI Therapy
- Gene Therapy
Global Hemophilia Market, By End User
- Hospital Pharmacy
- Retail Pharmacy
- Others
Global Hemophilia market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive hemophilia market market research and competitor analysis for your business to help you develop more profound insights into the hemophilia market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the hemophilia market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.